Table 2.

Univariate Analysis for Overall Survival, Disease Free Survival, and Local Control

		Overall Survival		Disease Free Survival		Local Control
Variable	No. (%)	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Figo Stage
III-IV	17 (45%)	2.5 (1.1-5.8)	0.024	2.7 (1.2-5.9)	0.014	2.3 (0.8-6.6)	0.123
I-II	21 (55%)
Age at Surgery
Continuous		1.0 (1.0-1.1)	0.091	1.0 (1.0-1.1)	0.243	1.0 (1.0-1.1)	0.384
>65	17 (45%)	1.8 (0.8-4.1)	0.158	1.4 (0.6-2.9)	0.427	1.2 (0.4-3.2)	0.776
≤ 65	21 (55%)
Histology
High Risk*	22 (58%)	1.0 (0.5-2.3)	0.953	1.5 (0.7-3.3)	0.291	2.1 (0.7-6.7)	0.207
Endometrial	16 (42%)
No. Recurrent Sites
> 1	24 (63%)	1.1 (0.5-2.5)	0.82	1.1 (0.5-2.5)	0.821	0.9 (0.3-2.4)	0.766
1	14 (37%)
Size of Largest Recurrence
Continuous		1.0 (0.8-1.2)	0.988	0.9 (0.8-1.1)	0.440	1.0 (0.8-1.3)	0.928
≥ 3 cm	17 (45%)	0.8 (0.4-1.9)	0.669	0.7 (0.3-1.4)	0.288	1.4 (0.5-3.8)	0.564
< 3 cm	21 (55%)
Initial Chemotherapy
Yes	13 (34%)	4.4 (1.7-11.6)	0.002	4.6 (2.0-10.8)	<0.001	4.9 (1.5-16.0)	0.008
No	25 (66%)
Concurrent Chemotherapy
Yes	21 (55%)	0.4 (0.2-1.0)	0.039	0.6 (0.3-1.2)	0.148	0.5 (0.2-1.30	0.158
No	17 (45%)
Total GTV Dose (Gy)
< 64.7	19 (50%)	1.2 (0.5-2.6)	0.663	1.9 (0.9-4.2)	0.099	3.2 (1.0-10.0)	0.048
≥ 64.7	19 (50%)
Initial Grade
3	11 (29%)	2.4 (1.0-6.0)	0.063	3.5 (1.4-8.9)	0.008	4.8 (1.1-20.8)	0.038
1, 2	21 (55%)
Type of Recurrence
Pelvic only	13 (34%)	1.0 (0.4-2.9)	0.935	1.0 (0.3-2.8)	0.961	1.2 (0.3-4.6)	0.807
Pelvic + other	17 (45%)	1.0 (0.4-2.9)	0.943	1.1 (0.4-3.0)	0.813	0.5 (0.1-2.3)	0.391
PAN only	8 (21%)
Time from TAH to Recurrence
Continuous		1.0 (0.99-1.01)	0.72	0.99 (0.98-1.01)	0.29	0.97 (0.93-1.0)	0.119
≤1 year	12 (32%)	2.6 (1.0-6.9)	0.053	2.7 (1.1-6.6)	0.025	3.4 (1.2-10.0)	0.027
>1 year	26 (68%)

^*High risk histology includes papillary serous, carcinosarcoma, and clear cell.

Abbreviations: HR, hazard ratio; CI, confidence interval; GTV, gross total volume; PAN, paraortic node; TAH, total abdominal hysterectomy.